2020
Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, Lauro K, Jurjus G, Pilkinton P, Davis L, Wilcox JA, Iranmanesh A, Sapra M, Aslam M, Michalets J, Thase M, Zisook S. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32603560, DOI: 10.4088/jcp.19m13038.Peer-Reviewed Original ResearchConceptsConcurrent posttraumatic stress disorderMajor depressive disorderPosttraumatic stress disorderDepressive disorderVeterans Health Administration medical centersNonpsychotic major depressive disorderStress disorderMini International Neuropsychiatric InterviewAdequate antidepressant treatmentPoor overall outcomeDepressive Symptomatology-Clinician RatedSevere depressive symptomsAntipsychotic augmentationInitial remissionAntidepressant treatmentSuboptimal responseAntipsychotic aripiprazoleCurrent antidepressantsAntidepressant trialsQuick InventoryNeuropsychiatric InterviewClinical trialsMedical CenterRemissionDepressive symptoms
2019
General Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2018
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 80 PMID: 30695291, DOI: 10.4088/jcp.18m12294.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationAripiprazoleBupropionCost-Benefit AnalysisDepressionDepressive Disorder, MajorDrug SubstitutionDrug SynergismDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRemission InductionUnited StatesUnited States Department of Veterans AffairsVeteransConceptsIncremental cost-effectiveness ratioStandard antidepressant therapyBupropion augmentationAripiprazole augmentationAntidepressant therapyClinical trialsVeterans Affairs Medical CenterDepression Outcomes trialMental health care costsRate of remissionRandomized clinical trialsHealth care sector perspectiveICD-9 codesTreatment of depressionCost-effectiveness ratioHealth care costsCost-effective relativeCost-effectiveness analysisOutcome trialsMean ageQuick InventoryDepression diagnosisTreatment strategiesRemissionMedical Center
2017
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAcute treatment phaseDepressive disorderSwitch groupAdverse effectsTreatment phaseUS Veterans Health Administration medical centersVeterans Health Administration medical centersNonpsychotic major depressive disorderWeeks of treatmentEffects of antidepressantsLikelihood of remissionSignificant treatment differencesBupropion monotherapyRandomized patientsRemission rateBupropion groupSecondary outcomesPrimary outcomeAtypical antipsychoticsDifferent antidepressantsFirst antidepressantClinical trialsCurrent treatmentMedical Center
2016
Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income
Rosenheck R, Mueser KT, Sint K, Lin H, Lynde DW, Glynn SM, Robinson DG, Schooler NR, Marcy P, Mohamed S, Kane JM. Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income. Schizophrenia Research 2016, 182: 120-128. PMID: 27667369, DOI: 10.1016/j.schres.2016.09.024.Peer-Reviewed Original ResearchConceptsCommunity carePublic support incomeFirst episode psychosis programUsual community careGeneral estimation equation modelsFirst-episode psychosisEstimation equation modelsPsychosis programPublic support paymentsEpisode psychosisTreatment clinicsDays of participationTreatment approachesFEP participantsIntegrated careStudy participantsTreatment programEvidence effectivenessMonthly assessmentsGroup differencesIndividual PlacementDisability incomeGreater improvementGreater increaseCareComparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China
Zhou Y, Rosenheck R, Mohamed S, Ou Y, Ning Y, He H. Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China. BMC Psychiatry 2016, 16: 283. PMID: 27515535, PMCID: PMC4980784, DOI: 10.1186/s12888-016-0962-y.Peer-Reviewed Original ResearchConceptsFamily burdenBipolar disorderPsychiatric hospitalDifference of burdenWeeks of patientsMethodsTwo hundred fortyCross-sectional studyFamilies of patientsAcute psychiatric hospitalLarge psychiatric hospitalBipolar disorder patientsQuality of lifeComparison of burdenClinical featuresAcute patientsPredictive factorsCaregiver burdenHundred fortyDisorder patientsSchizophrenic patientsBipolar patientsPatientsSchizophrenia patientsSuicidal riskCaregivers' perceptionsCharacteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report
Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. Journal Of Affective Disorders 2016, 206: 232-240. PMID: 27479536, DOI: 10.1016/j.jad.2016.07.023.Peer-Reviewed Original ResearchConceptsMajor depressive disorderClinical featuresDepressive disorderNonpsychotic major depressive disorderInitial standard treatmentNon-veteran samplesU.S. veteran patientsCharacteristics of patientsSample of veteransRecent suicidal ideationPublic health imperativeLasting treatmentMDD treatmentVeteran patientsClinical onsetPsychiatric comorbidityAntidepressant trialsStandard treatmentClinical trialsDepression subtypesRecurrent depressionIndividual patientsSpecific treatmentPatientsSuicidal ideationComparison of Intensive Case Management for Psychotic and Nonpsychotic Patients
Mohamed S. Comparison of Intensive Case Management for Psychotic and Nonpsychotic Patients. Psychological Services 2016, 13: 10-19. PMID: 26168139, DOI: 10.1037/ser0000041.Peer-Reviewed Original ResearchConceptsAssertive community treatmentPsychotic symptomsAnalysis of covariancePsychotic disordersIntensive case management programIntensive case management servicesSevere psychotic symptomsIntensive case managementCommunity-based careCase management programCase management servicesInpatient bed availabilityCommunity-based service programsBaseline characteristicsMedication complianceNonpsychotic patientsNonpsychotic disordersOutcome dataPsychotic diagnosesHospital useCommunity treatmentSuch symptomsBed availabilitySymptomsCase management
2015
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations
Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research 2015, 229: 760-770. PMID: 26279130, DOI: 10.1016/j.psychres.2015.08.005.Peer-Reviewed Original ResearchRandomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2015, 203: 486-492. PMID: 26075840, DOI: 10.1097/nmd.0000000000000317.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAntipsychotic AgentsBenzodiazepinesChronic DiseaseComorbidityCross-Sectional StudiesDibenzothiazepinesDouble-Blind MethodFemaleHumansIllicit DrugsMaleMiddle AgedOlanzapinePerphenazinePiperazinesPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaSchizophrenic PsychologySmokingSmoking PreventionSubstance-Related DisordersThiazolesYoung AdultConceptsSecond-generation antipsychotic drugsAntipsychotic drugsFirst-generation antipsychoticsSecond-generation antipsychoticsIntervention Effectiveness (CATIE) studySecondary outcome dataClinical Antipsychotic TrialsFirst-generation drugsSubstance use outcomesCigarette smokingSchizophrenia trialsChronic schizophreniaAntipsychotic TrialsOutcome dataNicotine useDrug useSecondary analysisPast weekAntipsychoticsEffectiveness studiesPatientsSubstance useUse outcomesTrialsDrugs
2014
Insight in inpatients with schizophrenia: Relationship to symptoms and neuropsychological functioning
Zhou Y, Rosenheck R, Mohamed S, Zhang J, Chang Q, Ou Y, Sun B, Ning Y, He H. Insight in inpatients with schizophrenia: Relationship to symptoms and neuropsychological functioning. Schizophrenia Research 2014, 161: 376-381. PMID: 25533592, DOI: 10.1016/j.schres.2014.12.009.Peer-Reviewed Original ResearchAssociation of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia
Zhang J, Rosenheck R, Mohamed S, Zhou Y, Chang Q, Ning Y, He H. Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia. Comprehensive Psychiatry 2014, 55: 1914-1919. PMID: 25217308, DOI: 10.1016/j.comppsych.2014.07.018.Peer-Reviewed Original ResearchConceptsPharmacologic side effectsSevere side effectsGreater medication complianceHigher medication dosagesPANSS total scoreSevere symptomsSide effectsMedication complianceMedication dosageITAQ scoresHigh dosesTotal scorePoor treatment complianceSide effect scoresLarge psychiatric hospitalRelationship of symptomsNegative Syndrome ScaleTreatment Attitudes QuestionnaireStepwise multiple linear regression analysisInteraction of symptomsInsightful patientsTreatment emergentHospital dischargePrescribed medicationsTreatment complianceInsight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China
Mohamed S, Rosenheck R, He H, Yuping N. Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China. Social Psychiatry And Psychiatric Epidemiology 2014, 49: 1063-1070. PMID: 24549835, DOI: 10.1007/s00127-014-0824-1.Peer-Reviewed Original ResearchConceptsDrug Attitude InventorySchizophrenia symptomsPsychiatric hospitalOverall severityMeasures of insightGuangzhou Psychiatric HospitalTime of admissionBenefits of medicationsLarge psychiatric hospitalNegative Syndrome ScaleTreatment Attitudes QuestionnaireSymptoms of schizophreniaAcceptance of medicationHospitalized patientsAntipsychotic treatmentDAI scoresChronic schizophreniaMedicationsAnalysis of covarianceSyndrome ScaleMental illnessBivariate analysisSymptomsLarger studySchizophrenia
2013
Correlates of readmission risk and readmission days in a large psychiatric hospital in Guangzhou, China
Zhou Y, Ning Y, Fan N, Mohamed S, Rosenheck RA, He H. Correlates of readmission risk and readmission days in a large psychiatric hospital in Guangzhou, China. Asia-Pacific Psychiatry 2013, 6: 342-349. PMID: 24038857, DOI: 10.1111/appy.12096.Peer-Reviewed Original ResearchConceptsGuangzhou Psychiatric HospitalReadmission riskHospital daysPrevious admissionsPsychiatric careRisk of readmissionTotal bed daysTotal hospital daysCox regression modelCourse of illnessCommunity-based careReadmission daysIndex dischargeFrequent relapsesMiddle-income countriesSuch patientsPrevious hospitalizationAverage LOSBed daysPast hospitalizationInternational ClassificationPsychiatric disordersOnly predictorPsychiatric diagnosisPsychiatric hospital
2012
Adaptation of Intensive Mental Health Intensive Case Management to Rural Communities in the Veterans Health Administration
Mohamed S. Adaptation of Intensive Mental Health Intensive Case Management to Rural Communities in the Veterans Health Administration. Psychiatric Quarterly 2012, 84: 103-114. PMID: 22729625, DOI: 10.1007/s11126-012-9231-5.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceCase ManagementCommunity Mental Health ServicesFemaleHealth Services AccessibilityHumansMaleMental DisordersMiddle AgedOutcome and Process Assessment, Health CarePatient SatisfactionProgram EvaluationQuality of LifeRural Health ServicesRural PopulationSeverity of Illness IndexSocial AdjustmentSocioeconomic FactorsSuicidal IdeationUnited StatesUnited States Department of Veterans AffairsVeterans HealthDoes Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression?
Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, Zisook S. Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression? Neuropsychobiology 2012, 65: 168-172. PMID: 22456094, PMCID: PMC3701889, DOI: 10.1159/000331141.Peer-Reviewed Original ResearchConceptsSchizoaffective disorderCognitive deficitsDepression Rating Scale scoresHamilton Depression Rating ScaleFlexible-dose treatmentAntidepressant treatment responseDepression Rating ScaleTreatment of depressionMajor depressive disorderRating Scale scoresBaseline cognitive statusPlacebo groupAntidepressant medicationCurrent medicationsPlacebo augmentationFunctional disabilityCognitive composite scoreSubsyndromal depressionDepressive disorderSubsyndromal symptomsTreatment responseTreatment groupsDose treatmentScale scoreCognitive status
2011
Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.
Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. The Journal Of Clinical Psychiatry 2011, 73: 121-8. PMID: 21939611, PMCID: PMC4040971, DOI: 10.4088/jcp.10m06574.Peer-Reviewed Original ResearchConceptsCaregiver Distress ScaleCaregivers of patientsSecond-generation antipsychoticsCaregiver burdenExperiences of caregiversAlzheimer's diseaseBurden InterviewDisease trialsNeuropsychiatric Inventory Caregiver Distress ScaleDistress ScaleCATIE-AD trialAtypical antipsychotic treatmentUsual care settingsAtypical antipsychotic drugsClinical Antipsychotic TrialsSymptoms of psychosisBeck Depression InventoryAD outpatientsTreat analysisAtypical antipsychoticsAntipsychotic treatmentAD patientsAntipsychotic drugsAntipsychotic TrialsCare settingsNarrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia
Osatuke K, Reid M, Stiles WB, Kasckow JW, Zisook S, Mohamed S. Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia. Psychotherapy Research 2011, 21: 41-53. PMID: 20845225, DOI: 10.1080/10503307.2010.508760.Peer-Reviewed Original ResearchAdaptation, PsychologicalAntidepressive Agents, Second-GenerationAntipsychotic AgentsAwarenessCitalopramDefense MechanismsDepressive DisorderDrug Therapy, CombinationHumansInternal-External ControlInterview, PsychologicalLongitudinal StudiesMaleMiddle AgedNarrationProblem SolvingPsychotherapySchizophreniaSchizophrenic Psychology
2010
Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates
Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates. American Journal Of Geriatric Psychiatry 2010, 18: 917-927. PMID: 20808108, PMCID: PMC3972419, DOI: 10.1097/jgp.0b013e3181d5745d.Peer-Reviewed Original ResearchConceptsAlzheimer's diseasePatients' qualityCaregiver burdenCognitive statusCaregiver Distress ScaleUsual care settingsIntensity of careLower functional capabilitySix-month changesClinical Antipsychotic TrialsProbable Alzheimer's diseasePatients' cognitive statusDiagnosis of dementiaQuality of lifeBeck Depression InventoryCATIE-ADRelationship of burdenBurden InterviewAmbulatory outpatientsPatients CorrelatePharmacologic interventionsAntipsychotic TrialsTreatment outcomesDecreased burdenCare settingsImpact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal Of Clinical Psychiatry 2010, 72: 75-80. PMID: 20868641, PMCID: PMC5052810, DOI: 10.4088/jcp.09m05258gre.Peer-Reviewed Original ResearchConceptsMajor depressive episodeSecond-generation antipsychoticsDSM-IV-defined schizophreniaCurrent major depressive episodeClinical practice recommendationsTrial of treatmentClinical practice guidelinesTreatment of depressionCalgary Depression ScaleClinical Antipsychotic TrialsSecond-generation drugsSymptoms of depressionPhase 1 analysisTardive dyskinesiaDepressive episodeChronic schizophreniaAntipsychotic TrialsPractice guidelinesDepression ScaleDepressive symptomsTreatment groupsBaseline scoresPatientsAntipsychoticsPractice recommendations